Halozyme Therapeutics (NASDAQ:HALO – Get Rating) issued an update on its FY22 earnings guidance on Wednesday morning. The company provided EPS guidance of $2.05-2.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.19. The company issued revenue guidance of $530-560 million, compared to the consensus revenue estimate of $553.50 million.Halozyme Therapeutics also updated its FY 2022 guidance to $2.050-$2.200 EPS.
A number of brokerages recently commented on HALO. Piper Sandler lowered their price objective on Halozyme Therapeutics from $43.00 to $42.00 in a research report on Wednesday, February 23rd. StockNews.com raised shares of Halozyme Therapeutics from a hold rating to a buy rating in a research note on Monday. Finally, Zacks Investment Research raised shares of Halozyme Therapeutics from a strong sell rating to a hold rating and set a $37.00 price objective on the stock in a research note on Monday, March 14th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of Buy and an average target price of $47.83.
NASDAQ HALO traded down $0.61 during trading on Wednesday, reaching $41.01. 14,337 shares of the stock traded hands, compared to its average volume of 895,423. Halozyme Therapeutics has a fifty-two week low of $31.36 and a fifty-two week high of $51.57. The company has a quick ratio of 7.45, a current ratio of 7.91 and a debt-to-equity ratio of 4.00. The firm has a market cap of $5.65 billion, a price-to-earnings ratio of 15.13 and a beta of 1.32. The stock’s 50-day moving average price is $36.66 and its 200 day moving average price is $36.85.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. increased its holdings in Halozyme Therapeutics by 0.7% during the 4th quarter. BlackRock Inc. now owns 19,439,863 shares of the biopharmaceutical company’s stock worth $781,676,000 after purchasing an additional 144,483 shares in the last quarter. Allianz Asset Management GmbH grew its holdings in shares of Halozyme Therapeutics by 4.5% during the fourth quarter. Allianz Asset Management GmbH now owns 586,274 shares of the biopharmaceutical company’s stock worth $23,575,000 after buying an additional 25,161 shares in the last quarter. Deutsche Bank AG raised its position in Halozyme Therapeutics by 6.3% in the 4th quarter. Deutsche Bank AG now owns 111,307 shares of the biopharmaceutical company’s stock valued at $4,476,000 after buying an additional 6,617 shares during the last quarter. California State Teachers Retirement System lifted its stake in Halozyme Therapeutics by 1.6% in the 4th quarter. California State Teachers Retirement System now owns 195,973 shares of the biopharmaceutical company’s stock valued at $7,880,000 after acquiring an additional 3,170 shares in the last quarter. Finally, Parametric Portfolio Associates LLC lifted its stake in Halozyme Therapeutics by 5.1% in the 4th quarter. Parametric Portfolio Associates LLC now owns 293,558 shares of the biopharmaceutical company’s stock valued at $11,804,000 after acquiring an additional 14,233 shares in the last quarter. 90.21% of the stock is owned by institutional investors and hedge funds.
About Halozyme Therapeutics (Get Rating)
Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
- Get a free copy of the StockNews.com research report on Halozyme Therapeutics (HALO)
- OrganiGram’s Turnaround Begins To Blossom
- Three Dividend Stocks With Growth Potential
- Exelon Stock Still Has Extraordinary Upside
- Greenbrier Companies Stock has Green in its Future
- Insiders Are Selling Palo Alto Networks
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.